Living Cell Technologies is engaged in the clinical development of cell based therapeutics for the treatment of diabetes and pre-clinical research and development into neurological disorders predominantly in New Zealand. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. The Company's lead product, DIABECELL®, consists of microencapsulated porcine islets which are implanted into a patient's abdomen using a simple laparoscopic procedure.Data provided by Mergent, Inc.
|Effective Date||Jul 17, 2007|
|Industry||Pharma. & Biotech.|